Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Digital PCR: A brief history.

Morley AA.

Biomol Detect Quantif. 2014 Aug 15;1(1):1-2. Review.

2.

Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2016 Mar 8;16(7):1-52. Review.

3.

Advances and issues in flow cytometric detection of immunophenotypic changes and genomic rearrangements in acute pediatric leukemia.

Wang XM.

Transl Pediatr. 2014 Apr;3(2):149-55. doi: 10.3978/j.issn.2224-4336.2014.03.06. Review.

4.

Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.

Wei W, Chen X, Zou Y, Chang L, An W, Wan Y, Liu T, Yang W, Chen Y, Guo Y, Zhu X.

BMC Pediatr. 2015 Jul 15;15:80. doi: 10.1186/s12887-015-0390-z.

5.

Measurements of treatment response in childhood acute leukemia.

Campana D, Coustan-Smith E.

Korean J Hematol. 2012 Dec;47(4):245-54. doi: 10.5045/kjh.2012.47.4.245.

6.

Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Gaipa G, Cazzaniga G, Valsecchi MG, Panzer-Grümayer R, Buldini B, Silvestri D, Karawajew L, Maglia O, Ratei R, Benetello A, Sala S, Schumich A, Schrauder A, Villa T, Veltroni M, Ludwig WD, Conter V, Schrappe M, Biondi A, Dworzak MN, Basso G.

Haematologica. 2012 Oct;97(10):1582-93. doi: 10.3324/haematol.2011.060426.

7.

A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.

Han BW, Feng DD, Li ZG, Luo XQ, Zhang H, Li XJ, Zhang XJ, Zheng LL, Zeng CW, Lin KY, Zhang P, Xu L, Chen YQ.

Hum Mol Genet. 2011 Dec 15;20(24):4903-15. doi: 10.1093/hmg/ddr428.

8.

Chemotherapeutic resistance: surviving stressful situations.

Gilbert LA, Hemann MT.

Cancer Res. 2011 Aug 1;71(15):5062-6. doi: 10.1158/0008-5472.CAN-11-0277.

9.

Noninvasive identification of subcellular organization and nuclear morphology features associated with leukemic cells using light-scattering spectroscopy.

Hsiao A, Hunter M, Greiner C, Gupta S, Georgakoudi I.

J Biomed Opt. 2011 Mar;16(3):037007. doi: 10.1117/1.3562925.

10.

Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Coustan-Smith E, Campana D.

Best Pract Res Clin Haematol. 2010 Sep;23(3):347-58. doi: 10.1016/j.beha.2010.07.007. Review.

11.

Progress of minimal residual disease studies in childhood acute leukemia.

Campana D.

Curr Hematol Malig Rep. 2010 Jul;5(3):169-76. doi: 10.1007/s11899-010-0056-8. Review.

12.

Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Campana D.

Hematol Oncol Clin North Am. 2009 Oct;23(5):1083-98, vii. doi: 10.1016/j.hoc.2009.07.010. Review.

13.

Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA.

J Mol Diagn. 2009 May;11(3):194-200. doi: 10.2353/jmoldx.2009.080047.

14.

Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.

Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, Wilczek V, Budgen B, van Zanten K, Kuss BJ, Venn NC, Norris MD, Crock C, Storey C, Revesz T, Waters K.

J Mol Diagn. 2009 May;11(3):201-10. doi: 10.2353/jmoldx.2009.080048.

15.

Minimal residual disease in acute lymphoblastic leukemia.

Campana D.

Semin Hematol. 2009 Jan;46(1):100-6. doi: 10.1053/j.seminhematol.2008.09.001. Review.

16.

Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.

Mosad E, Hamed HB, Bakry RM, Ezz-Eldin AM, Khalifa NM.

J Hematol Oncol. 2008 Oct 17;1:17. doi: 10.1186/1756-8722-1-17.

17.

Status of minimal residual disease testing in childhood haematological malignancies.

Campana D.

Br J Haematol. 2008 Nov;143(4):481-9. doi: 10.1111/j.1365-2141.2008.07350.x. Review.

18.

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD, Sallan SE, Silverman LB, Gribben JG; Dana-Farber Cancer Institute ALL Consortium..

Blood. 2007 Sep 1;110(5):1607-11.

19.

The study of minimal residual disease in acute lymphoblastic leukaemia.

Knechtli CJ, Goulden NJ, Langlands K, Potter MN.

Clin Mol Pathol. 1995 Apr;48(2):M65-73. No abstract available.

Supplemental Content

Support Center